Discover our latest news
Articles
AP1 and AP2 in France: What Biopharma Companies Need to Know
AP1 and AP2 are France's Early Access pathways for innovative medicines before and after marketing authorization. Learn eligibility,…
Read more
White Papers
Navigating the New EU Pharma Package, Part 1
What the new EU pharma rules change for protection, orphans, pediatrics and EMA pathways, and which decisions can't…
Read more
Articles
We’re proud to share that we have been published in the Regulatory Affairs Professionals Society (RAPS) Journal of Regulatory Affairs.
In this article, our experts Samantha Gastine, Anne-Valérie Faucher and Nadia Boehringer examines the evolving pediatric regulatory landscape…
Read more